Literature DB >> 34512788

Cytology of peritoneal implants of borderline serous tumor of ovaries in ascitic fluid.

Sudha Sharma1, Dibyanshu Sekhar Mohapatra1, Nalini Gupta1, Radhika Srinivasan1, Arvind Rajwanshi1, Pranab Dey1.   

Abstract

OBJECTIVES: Peritoneal fluid cytology is done routinely in cases with serous carcinoma of ovary. However, morphologic features of borderline serous tumors (BSTs) of ovary in ascitic fluid have been rarely described. The aim of our study was to evaluate the morphologic features of BST with and without ascitic fluid involvement (BST+ and BST-, respectively) and compare with those of serous carcinomas, both in conventional and liquid-based cytology (LBC) smears.
MATERIAL AND METHODS: Out of 30 BST cases reported in 3 years, seven cases had BST+. We compared the cytomorphology of seven cases of BST+, seven cases of BST-, and seven cases of serous adenocarcinoma with positive ascitic fluid cytology. Both conventional and LBC smears were studied in all cases and compared. Histopathology of omentum in these cases was also studied.
RESULTS: Most cases with BST+ had regular papillary fragment borders with nuclei showing mild-to-moderate pleomorphism, fine nuclear chromatin with small nucleoli as compared with serous carcinomas all of which had irregular borders with moderate-to-severe nuclear pleomorphism, coarse chromatin, and macronucleoli.
CONCLUSION: A combination of cytoarchitectural and nuclear features can help in suspecting BST in ascitic fluid. Ascitic fluid cytology together with tissue histology can increase the rate of the detection of peritoneal implants.
© 2021 Cytopathology Foundation Inc, Published by Scientific Scholar.

Entities:  

Keywords:  Ascitic fluid; Borderline serous tumors; Liquid-based cytology; Ovary

Year:  2021        PMID: 34512788      PMCID: PMC8422453          DOI: 10.25259/Cytojournal_56_2020

Source DB:  PubMed          Journal:  Cytojournal        ISSN: 1742-6413            Impact factor:   2.091


  9 in total

1.  Ovarian serous borderline tumors: a critical review of the literature with emphasis on prognostic indicators.

Authors:  J D Seidman; R J Kurman
Journal:  Hum Pathol       Date:  2000-05       Impact factor: 3.466

2.  Cytohistologic correlation in malignant peritoneal washings. Analysis of 75 malignant fluids.

Authors:  N Mulvany
Journal:  Acta Cytol       Date:  1996 Nov-Dec       Impact factor: 2.319

3.  Peritoneal washing cytology in gynecologic cancers: long-term follow-up of 355 patients.

Authors:  R E Zuna; A Behrens
Journal:  J Natl Cancer Inst       Date:  1996-07-17       Impact factor: 13.506

Review 4.  Borderline ovarian tumours.

Authors:  Claes Göran Tropé; Janne Kaern; Ben Davidson
Journal:  Best Pract Res Clin Obstet Gynaecol       Date:  2012-02-07       Impact factor: 5.237

5.  Peritoneal fluid cytology in patients with ovarian cancer.

Authors:  S Yoshimura; R E Scully; P D Taft; J B Herrington
Journal:  Gynecol Oncol       Date:  1984-02       Impact factor: 5.482

6.  Pelvic washing cytology in serous borderline tumors of the ovary using ThinPrep: are there cytologic clues to detecting tumor cells?

Authors:  Saha Sadeghi; Lourdes R Ylagan
Journal:  Diagn Cytopathol       Date:  2004-05       Impact factor: 1.582

7.  Ovarian serous borderline tumors with noninvasive and invasive peritoneal implants: A case report each.

Authors:  Banushree C Srinivasamurthy; Ambedkar Raj Kulandai Velu; Nagarajan Krishnan; Anand Shankar Rao Patil
Journal:  J Cancer Res Ther       Date:  2015 Jul-Sep       Impact factor: 1.805

8.  Peritoneal washing cytology of ovarian tumors of low malignant potential: correlation with surface ovarian involvement and peritoneal implants.

Authors:  L Cheng; N G Wolf; P G Rose; M Rodriguez; F W Abdul-Karim
Journal:  Acta Cytol       Date:  1998 Sep-Oct       Impact factor: 2.319

9.  Abdominopelvic washings: A comprehensive review.

Authors:  Erika F Rodriguez; Sara E Monaco; Walid Khalbuss; R Marshall Austin; Liron Pantanowitz
Journal:  Cytojournal       Date:  2013-04-24       Impact factor: 2.091

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.